An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3

Trial Profile

An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs A002-MeiraGTx (Primary)
  • Indications Colour vision defects
  • Focus Adverse reactions; First in man
  • Acronyms CNGB3
  • Sponsors MeiraGTx
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
    • 07 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
    • 24 Aug 2017 According to a MeiraGTx media release, the first patient in the 2nd cohort has also been treated at Moorfields Eye Hospital.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top